Article Text

Download PDFPDF

Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections
Free
  1. Petra Zimmermann1,2,3,
  2. Nigel Curtis3,4,5
  1. 1 Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
  2. 2 Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland
  3. 3 Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia
  4. 4 Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia
  5. 5 Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia
  1. Correspondence to Dr Petra Zimmermann, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland; petra.zimmermann{at}unifr.ch

Abstract

In contrast to other respiratory viruses, children have less severe symptoms when infected with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we discuss proposed hypotheses for the age-related difference in severity of coronavirus disease 2019 (COVID-19).

Factors proposed to explain the difference in severity of COVID-19 in children and adults include those that put adults at higher risk and those that protect children. The former include: (1) age-related increase in endothelial damage and changes in clotting function; (2) higher density, increased affinity and different distribution of angiotensin converting enzyme 2 receptors and transmembrane serine protease 2; (3) pre-existing coronavirus antibodies (including antibody-dependent enhancement) and T cells; (4) immunosenescence and inflammaging, including the effects of chronic cytomegalovirus infection; (5) a higher prevalence of comorbidities associated with severe COVID-19 and (6) lower levels of vitamin D. Factors that might protect children include: (1) differences in innate and adaptive immunity; (2) more frequent recurrent and concurrent infections; (3) pre-existing immunity to coronaviruses; (4) differences in microbiota; (5) higher levels of melatonin; (6) protective off-target effects of live vaccines and (7) lower intensity of exposure to SARS-CoV-2.

  • epidemiology
  • microbiology
  • virology

Data availability statement

No data are available.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

No data are available.

View Full Text

Footnotes

  • Twitter @Dr_Petzi, @nigeltwitt

  • Contributors PZ drafted the initial manuscript. NC contributed to the writing and critical revision of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.